GlassScriptPhysician profile
Yunmin Chen
NPI 1043823347
$4,322.24
in general payments reported to CMS, 2019-2025
27 companies · $617 in 2025
The $617 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $16.03 · 2023: $2,189 · 2024: $1,500 · 2025: $617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,306.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,306.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,160.45 | 2023-2025 | |
| Novo Nordisk INC | $418.48 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $373.86 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $313.14 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $303.14 | 2023-2025 | Otezla, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $292.92 | 2023-2024 | Xarelto, Spravato |
| Glaxosmithkline, LLC. | $243.31 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Exact Sciences Corporation | $239.08 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $205.36 | 2023-2024 | |
| Corium, LLC | $133.19 | 2023 | Azstarys |
| Harmony Biosciences LLC | $124.16 | 2024 | |
| Novartis Pharmaceuticals Corporation | $76.15 | 2023-2024 | |
| Esperion Therapeutics, INC. | $62.67 | 2023-2024 | Nexletol |
| Merck Sharp & Dohme LLC | $52.31 | 2023-2025 | Verquvo, Gardasil 9 |
| Ge Healthcare | $46.07 | 2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $34.16 | 2024 | |
| Almatica Pharma LLC | $31.69 | 2023 | Gralise, Loreev Xr, Sertraline Hcl |
| Axsome Therapeutics, INC. | $31.65 | 2024 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $29.46 | 2024 | Rexulti |
| Scpharmaceuticals INC. | $24.58 | 2025 | |
| Edwards Lifesciences Corporation | $23.95 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Hologic Sales and Service, LLC | $22.54 | 2024 | Aptima |
| Radius Health, INC. | $19.50 | 2024 | Tymlos |
| Kyowa Kirin, INC. | $16.53 | 2023 | Crysvita |
| Biomarin Pharmaceutical INC. | $16.03 | 2022 | |
| Currax Pharmaceuticals LLC | $14.16 | 2023 | Contrave |
| Corcept Therapeutics | $13.70 | 2025 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yunmin Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.